Tilray (NASDAQ:TLRY) is one of the latest cannabis companies to push into the retail space.

On Thursday (August 29), the BC-based cannabis firm announced it had signed a deal to acquire all of the issued and outstanding securities of 420 Investments (FOUR20) in an all-share agreement valued at C$110 million.


FOUR20 is an adult-use cannabis retail operator based in Calgary, Alberta, and currently has six active brick-and-mortar locations in the province.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Shares of the company opened at US$27.61 on Thursday. Tilray prices saw a bit of fluctuation over the trading day eventually closing at US$26.74, representing a price decrease of 1.69 percent for the day

Tilray shares have slumped sharply in August following its Q2 2019 earnings report, in which the company posted a net loss of US$35.1 million, or US$0.36 per share, for the quarter. The company reached a year-high of US$100.15 in mid-January, since then the value of its shares has dropped by 73 percent.

Tilray will give FOUR20 C$70 million in class 2 common shares when the deal is completed and an additional C$40 million in common shares with the achievement of certain performance milestones.

The deal is set to be completed by the end of the first quarter of 2020.

In addition to its current lineup of stores, FOUR20 is also bringing 16 secured locations across Alberta as part of the transaction. These stores are planned to open in Canmore, Calgary and Edmonton, according to Tilray.

In February, FOUR20 reported it had reached C$5 million in sales, an amount based off of two operating locations in Calgary.

While the retailer only holds assets in Alberta, the marijuana producer said it plans on using FOUR20’s retail expertise to expand into other provincial markets in Canada.

Tilray’s chief corporate development officer Andrew Pucher said his company aims to enhance the purchasing experience for consumers as the market prepares for the legalization of edibles and infused products later this year.

Tilray will be completing the deal through its subsidiary, High Park Holdings, which will be subject to regulatory, shareholder and court approval.

Once the transaction is completed, FOUR20 will operate as a wholly-owned subsidiary of Tilray. The producer also indicated the store would offer branded products under the High Park name.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

FOUR20’s current stores are minimalist in their style and boast teams of experts to help consumers with their purchases.

Alberta’s marijuana market has been highly active since Canada legalized the recreational use of cannabis. Between October 2018 and June 2019, the western Canadian province spent the most on recreational cannabis in the country at C$123.7 million, recent data from Statistics Canada shows.

Ontario and Quebec came in second and third place with C$121.6 million and C$119.2 million spent, respectively. The Northwest Territories spent the least at C$14.7 million.

Alberta also has the most retail locations for legal marijuana in the country, totaling at 277 stores. Ontario is a distant second with 75 stores having just given out 42 retail licenses as part of its recent second lottery.

Tilray’s results for its Q2 2019 period noted a 371.1 percent increase in revenue to US$45.9 million compared with the same earnings report from last year. The company attributed the increase, in part, to the acquisition of Manitoba Harvest in February. According to the press release, Manitoba Harvest is the world’s largest producer of hemp food products and distributes a variety of hemp-based consumer goods in over 16,000 stores across Canada and the US.

While total revenue was at US$42 million excluding excise tax, the producer still reported net losses of US$35.1 million, or US$0.36 per share, for the quarter.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less